{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chiron D"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["1022-35"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4155003"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(9)"],"pubmed_abstract":["<h4>Unlabelled</h4>Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K-AKT act"],"journal":["Cancer discovery"],"pubmed_title":["Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma."],"pmcid":["PMC4155003"],"funding_grant_id":["R21 CA176362","T32 GM083937"],"pubmed_authors":["Sharman J","Elemento O","Mason CE","Chiron D","Di Liberto M","Chang B","Blecua P","Eng K","Huang X","Vijay P","Ali S","Chen-Kiang S","Martin P","Johnson A","Ely S","Leonard JP","Mathew S"],"additional_accession":[]},"is_claimable":false,"name":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.","description":"<h4>Unlabelled</h4>Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K-AKT act","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Sep","modification":"2026-04-16T17:49:10.876Z","creation":"2019-03-27T01:35:13Z"},"accession":"S-EPMC4155003","cross_references":{"pubmed":["25082755"],"doi":["10.1158/2159-8290.CD-14-0098","10.1158/2159-8290.cd-14-0098"]}}